ibrutinib,venetoclax,obinutuzumab
abbvie,janssen,roche
['cll', 'obinu', 'venetoclax', ' ibru']
dr. henriette huber presents on frontline triplet tx w/ obinu/ibrutinib/venetoclax in pts w/ cll w/ del17p/tp53 mut (length of tx 12 months if early mrd-neg cr and ibrutinib month 13-36 if not) -&gt; 100% orr, bm mrd undetectable 66% after c15, efs/os below. #ash22 #cllsm 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????